STOCKHOLM, Sweden--(BUSINESS WIRE)--The biopharma company Biovitrum (STO:BVT), listed on the Stockholm Stock Exchange since September 15, 2006, entered an agreement with the Uppsala-based biotech company Synphora in the autumn of 2006 regarding a new drug candidate (JB991) for the treatment of the skin disease psoriasis and other conditions. A clinical Phase II study of this drug candidate is now underway, and the results are expected to be known during second half of 2007.
